Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Up 60.7% in March

Alpha Tau Medical Ltd. (NASDAQ:DRTS) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 122,000 shares, a growth of 60.7% from the February 28th total of 75,900 shares. Based on an average daily trading volume, of 89,000 shares, the short-interest ratio is presently 1.4 days. Currently, 0.2% of the shares of the company are short sold.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of DRTS. Renaissance Technologies LLC increased its stake in Alpha Tau Medical by 188.7% in the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock valued at $127,000 after buying an additional 26,800 shares during the last quarter. Northern Trust Corp increased its position in shares of Alpha Tau Medical by 112.6% during the fourth quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock valued at $151,000 after acquiring an additional 25,770 shares during the last quarter. Finally, Levin Capital Strategies L.P. increased its position in shares of Alpha Tau Medical by 2.3% during the fourth quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock valued at $975,000 after acquiring an additional 7,189 shares during the last quarter. Institutional investors and hedge funds own 2.65% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $9.00 price target on shares of Alpha Tau Medical in a research note on Monday, March 17th.

Alpha Tau Medical Price Performance

NASDAQ DRTS traded down $0.10 during trading hours on Friday, reaching $2.56. The company’s stock had a trading volume of 25,356 shares, compared to its average volume of 48,716. Alpha Tau Medical has a 52 week low of $1.75 and a 52 week high of $4.39. The stock has a market cap of $180.18 million, a P/E ratio of -5.95 and a beta of 0.87. The firm has a fifty day simple moving average of $3.08 and a 200-day simple moving average of $2.81.

Alpha Tau Medical (NASDAQ:DRTS) last released its quarterly earnings results on Wednesday, March 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13). On average, research analysts expect that Alpha Tau Medical will post -0.45 earnings per share for the current year.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.